SCHEMBL2596535

SCHEMBL2596535

CC(=O)Oc1cc(O)cc(O)c1C(C)=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 8/20 0.63
MEN1 O00255 4/20 0.63
KMT2A Q03164 4/20 0.63
HPGD P15428 2/20 0.63
SMN1; SMN2 Q16637 2/20 0.53
MAPK1 P28482 2/20 0.53
USP2 O75604 1/20 0.53
SLC28A3 Q9HAS3 2/20 0.48
POLB P06746 2/20 0.47
NR1H2 P55055 1/20 0.43
NR1H3 Q13133 1/20 0.43
SYNJ2 O15056 1/20 0.42
PTGS1 P23219 1/20 0.42
DRD3 P35462 1/20 0.42
ACHE P22303 2/20 0.42
FASN P49327 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
ALDH1A1 P00352 1/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6023659 0.90 CYP3A4 (0.52) CYP3A4MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL29757572 0.82 CYP3A4 (0.76) CYP3A4MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL1937218 0.82 CYP3A4 (0.76) CYP3A4MEN1KMT2AHPGDSMN1; SMN2
2,4,6-Trihydroxyacetophenone SCHEMBL105416 0.79 CYP3A4 (1.00) CYP3A4MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL2066003 0.78 POLB (0.44) CYP3A4MEN1KMT2AHPGDPOLB
2,4,6-Trihydroxyacetophenone SCHEMBL27884985 0.77 CYP3A4 (0.86) CYP3A4MEN1KMT2AHPGDSMN1; SMN2
2,4,6-Trihydroxyacetophenone SCHEMBL1421619 0.77 CYP3A4 (0.95) CYP3A4MEN1KMT2AHPGDSMN1; SMN2
2,4,6-Trihydroxyacetophenone SCHEMBL564755 0.77 CYP3A4 (0.95) CYP3A4MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL8765619 0.75 TOP1 (0.53) CYP3A4MEN1KMT2AHPGDMAPK1
SCHEMBL24209302 0.75 MEN1 (0.55) CYP3A4MEN1KMT2AHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12098433-B2 On demand, portable, cell-free molecular sensing platform NORTHWESTERN UNIVERSITY (US) 2024-09-24 US claimed
EP-4189094-A2 CURE ALL FOR NUCLEIC ACID-GUIDED CELL EDITING IN E. COLI Inscripta, Inc. (US) 2023-06-07 EP claimed
WO-2022025974-A2 CURE ALL FOR NUCLEIC ACID-GUIDED CELL EDITING IN E. COLI INSCRIPTA, INC. (US) 2022-02-03 WO claimed
US-20220025359-A1 Cure all for nucleic acid-guided cell editing in E. Coli INSCRIPTA, INC. 2022-01-27 US claimed
US-20200054021-A1 A PROCESS OF CONSTRUCTING SPECIFIC FUNCTIONAL MICROBIOMES FOR PROMOTING PLANT GROWTH, PLANT AND SOIL HEALTH, BIOCONTROL AND BIOREMEDIATION MICROGEN BIOTECH (IE) 2020-02-20 US claimed
WO-2018153447-A1 A PROCESS OF CONSTRUCTING SPECIFIC FUNCTIONAL MICROBIOMES FOR PROMOTING PLANT GROWTH, PLANT AND SOIL HEALTH, BIOCONTROL AND BIOREMEDIATION. MICROGEN BIOTECH (IE) 2018-08-30 WO claimed
CN-103179976-A Glucagon superfamily peptides exhibiting g protein-coupled receptor activity MARCADIA BIOTECH INC 2013-06-26 CN claimed
US-20130116172-A1 GLUCAGON SUPERFAMILY PEPTIDES EXHBITING G PROTEIN COUPLED RECEPTOR ACTIVITY MARCADIA BIOTECH, INC. (US) 2013-05-09 US claimed
EP-2568993-A1 GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY Indiana University Research and Technology Corporation (US) 2013-03-20 EP claimed
WO-2011143208-A1 GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2011-11-17 WO claimed
US-6365406-B1 Enhancers of net photosynthesis and methods of enhancing net photosynthesis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2002-04-02 US claimed
JP-4124129-A None JP disclosed
CN-121574884-A Lecaniella albopictus Jou-S14 and application thereof 江苏海洋大学 2026-02-27 CN disclosed
WO-2025129053-A1 METHODS AND COMPOSITIONS FOR BIOPRODUCTION OF PHLOROGLUCINOL Debut Biotechnology, Inc. (US) 2025-06-19 WO disclosed
US-20240360485-A1 PROCESS FOR PREPARATION OF PHLOROGLUCINOL AND PHENOLIC DERIVATIVES EHRHARDT JEFFREY (US) 2024-10-31 US disclosed
US-6365406-B1 Enhancers of net photosynthesis and methods of enhancing net photosynthesis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2002-04-02 US disclosed
CN-1330695-A Coated biologically active grains CHISSO CORP (JP) 2002-01-09 CN disclosed
WO-2000029607-A1 NOVEL ENHANCERS OF PLANT GROWTH THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-05-25 WO disclosed
WO-2000029607-A1 NOVEL ENHANCERS OF PLANT GROWTH THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-05-25 WO disclosed
JP-H04124129-A ANTI-HERPES VIRUS AGENT TADA MASAHIRO 1992-04-24 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116172-A1 GLUCAGON SUPERFAMILY PEPTIDES EXHBITING G PROTEIN COUPLED RECEPTOR ACTIVITY GCGR, GLP1R, GIPR CYP3A4 4227/4885MEN1 2560/4885KMT2A 4036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.